Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 01167 JACOBIO-B > Main Composition
01167 JACOBIO-B
4.570
+0.060+1.33%
All
YOY
Do not show
Business Unit:CNY

Loading...

Product

Loading...

Region

Loading...

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

Company Overview More
Jiakos Pharmaceutical Group Co., Ltd. is committed to providing breakthrough treatment solutions for patients, and the company's vision is to work with partners to become a globally recognized leader in drug research and development. The company's laboratories are located in Beijing, China and Massachusetts, USA, and the experimental platform has allosteric inhibitors for the development of protein phosphatase, KRAS and other transcription factors. Garkos has received investment from several biotechnology investment institutions, including QiMing Venture Partners, Lilly Asia Fund, Hillhouse and Taiwan Yusheng.
CEO: Yinxiang Wang
Market: Hong Kong motherboard
Listing Date: 12/21/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist